#Japan #Drug Discovery #Shonan #genOway #Shonan Health

genOway's Strategic Move into Shonan Health Innovation Park

On July 1, 2026, genOway Japan Co., Ltd. will officially become a member of the Shonan Health Innovation Park, a pioneering platform designed to foster collaborative innovation in the pharmaceutical and biotechnology sectors. This membership marks a significant step for genOway, a global leader specializing in the design and development of humanized mouse models tailored for immune system research.

Advancing Drug Discovery with Quality Models

genOway is renowned for providing high-quality humanized models that enhance predictability in drug discovery. Among its offerings, the next-generation immune system humanized mouse model, particularly the “BRGSF-HIS” model, is highly acclaimed for its contributions to areas like tumor immunology. In contemporary drug discovery, where success rates are alarmingly low, improving human extrapolation in preclinical trials has never been more crucial.

By employing meticulous genetic design and stringent validation processes, genOway develops models that more accurately replicate human biological responses. This initiative aids in bridging the gap between preclinical and clinical phases, which is vital for the development of innovative pharmaceuticals. In fact, these models have been instrumental in the creation of breakthrough treatments such as the immune checkpoint inhibitor Opdivo (nivolumab).

Strengthening Collaborations for Innovation

Through its participation in Shonan Health Innovation Park, genOway aims to bolster its collaborations with domestic and international pharmaceutical firms, biotechnology companies, and academic institutions. The synergy created through these partnerships is expected to expedite the generation of innovations originating in Japan. By providing highly predictive preclinical models, genOway contributes to the efficiency of the drug discovery process and aims to improve the likelihood of successful outcomes, ultimately leading to the early practical use of revolutionary medications.

About Shonan Health Innovation Park

For more information on Shonan Health Innovation Park, visit shonan-ipark.com. Established in April 2018, this science park was initiated by Takeda Pharmaceutical Company, which opened its research facilities to foster collaboration. It serves as a hub where various industries, sizes, and sectors converge to accelerate health innovation. Currently, about 220 companies, including those in pharmaceuticals, next-generation medicine, cellular agriculture, AI, and government organizations, have established a life science ecosystem here, employing around 3,500 people as of June 2026.

About genOway

For more details, visit genoway.com. genOway is a biotechnology company focusing on the design and development of genetically modified mice and rats, expanding its global reach by delivering high-quality in vivo models for drug discovery research. Leveraging its proprietary genetic engineering technologies and comprehensive validation processes, genOway successfully develops models with high human extrapolability. These humanized mouse models are utilized across various fields, including immuno-oncology, autoimmune diseases, and infectious diseases, and are prominently adopted by leading pharmaceutical and biotech firms worldwide. Through its platform aimed at enhancing the success rates of drug discovery research, genOway significantly contributes to the creation of innovative therapies and improved patient outcomes.